{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:42:32Z","timestamp":1791052952976,"version":"4.1.0"},"reference-count":55,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.12666","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T11:32:17Z","timestamp":1570188737000},"page":"e1912666","source":"Crossref","is-referenced-by-count":74,"title":["Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes"],"prefix":"10.1001","volume":"2","author":[{"given":"Dawn","family":"Maze","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada"},{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajida","family":"Kazi","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Hematology, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada"},{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Kinga","family":"Malinowski","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Maternal\u2013Fetal Medicine, Department of Obstetrics & Gynaecology, Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouhi","family":"Fazelzad","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada"},{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakesh S.","family":"Shah","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Shehata","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2019,10,4]]},"reference":[{"key":"zoi190487r1","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/S0049-3848(13)70011-2","article-title":"Management of pregnant women with myeloproliferative neoplasms.","volume":"131","author":"Lavi","year":"2013","journal-title":"Thromb Res"},{"issue":"4","key":"zoi190487r2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1053\/j.seminhematol.2005.05.022","article-title":"Essential thrombocythemia.","volume":"42","author":"Finazzi","year":"2005","journal-title":"Semin Hematol"},{"issue":"11","key":"zoi190487r3","first-page":"1477","article-title":"The management and outcome of 18 pregnancies in women with polycythemia vera.","volume":"90","author":"Robinson","year":"2005","journal-title":"Haematologica"},{"issue":"1","key":"zoi190487r4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/bjh.14289","article-title":"Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study.","volume":"175","author":"Alimam","year":"2016","journal-title":"Br J Haematol"},{"issue":"9","key":"zoi190487r5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/17474086.2018.1506325","article-title":"Contemporary management of patients with BCR-ABL1\u2013negative myeloproliferative neoplasms during pregnancy.","volume":"11","author":"Griesshammer","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"zoi190487r6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.blre.2008.03.007","article-title":"Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy.","volume":"22","author":"Griesshammer","year":"2008","journal-title":"Blood Rev"},{"issue":"3","key":"zoi190487r7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/bjh.2005.129.issue-3","article-title":"Pregnancy and its management in the Philadelphia negative myeloproliferative diseases.","volume":"129","author":"Harrison","year":"2005","journal-title":"Br J Haematol"},{"issue":"3","key":"zoi190487r8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1034\/j.1600-0609.2000.90214.x","article-title":"Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies.","volume":"65","author":"Bangerter","year":"2000","journal-title":"Eur J Haematol"},{"issue":"1","key":"zoi190487r9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/ajo.2000.40.issue-1","article-title":"Management of essential thrombocythaemia during pregnancy.","volume":"40","author":"Cincotta","year":"2000","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"5","key":"zoi190487r10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/ejh.2009.82.issue-5","article-title":"Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies.","volume":"82","author":"Gangat","year":"2009","journal-title":"Eur J Haematol"},{"issue":"10","key":"zoi190487r11","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/ajh.v84:10","article-title":"Outcome of 122 pregnancies in essential thrombocythemia patients: a report from the Italian registry.","volume":"84","author":"Melillo","year":"2009","journal-title":"Am J Hematol"},{"issue":"4","key":"zoi190487r12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"issue":"15","key":"zoi190487r13","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group.","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"issue":"7650","key":"zoi190487r15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"23","key":"zoi190487r17","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1182\/blood-2013-10-531665","article-title":"Causal role for JAK2 V617F in thrombosis.","volume":"122","author":"Fleischman","year":"2013","journal-title":"Blood"},{"issue":"3","key":"zoi190487r18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"7414","key":"zoi190487r19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"zoi190487r21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3324\/haematol.2017.174672","article-title":"Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.","volume":"103","author":"Birgeg\u00e5rd","year":"2018","journal-title":"Haematologica"},{"key":"zoi190487r22","first-page":"260","article-title":"Pregnancy in women with myeloproliferative neoplasms.","volume":"27","author":"Polushkina","year":"2014","journal-title":"J Matern Fetal Neonatal Med"},{"key":"zoi190487r23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3324\/haematol.2014.115733","article-title":"Risk of pregnancy complications and effect of different treatments in women with essential thrombocythemia: a retrospective monocenter analysis of 62 pregnancies.","volume":"100","author":"Betti","year":"2015","journal-title":"Haematologica"},{"key":"zoi190487r24","first-page":"S110","article-title":"Outcomes of 121 pregnancies in patients with polycythemia vera (PV).","volume":"135413","author":"Griesshammer","year":"2016","journal-title":"EHA Library"},{"key":"zoi190487r25","first-page":"55","article-title":"Myeloproliferative neoplasms in patients below 25 years old at diagnosis: a single centre experience.","volume":"181","author":"Ianotto","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"zoi190487r26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ajh.v89.3","article-title":"Pregnancy complications predict thrombotic events in young women with essential thrombocythemia.","volume":"89","author":"Randi","year":"2014","journal-title":"Am J Hematol"},{"issue":"5","key":"zoi190487r27","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.3324\/haematol.2015.139691","article-title":"Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety: a case series.","volume":"101","author":"Beauverd","year":"2016","journal-title":"Haematologica"},{"issue":"9","key":"zoi190487r28","doi-asserted-by":"publisher","first-page":"E234","DOI":"10.1002\/ajh.v93.9","article-title":"Pregnancy outcome and management of 25 pregnancies in women with polycythemia vera.","volume":"93","author":"Bertozzi","year":"2018","journal-title":"Am J Hematol"},{"issue":"3","key":"zoi190487r29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ajh.10068","article-title":"Pregnancy and abortion in women with essential thrombocythemia.","volume":"69","author":"Candoni","year":"2002","journal-title":"Am J Hematol"},{"issue":"10","key":"zoi190487r30","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1182\/blood-2011-08-371328","article-title":"Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome.","volume":"119","author":"Giona","year":"2012","journal-title":"Blood"},{"issue":"4","key":"zoi190487r31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.gyobfe.2011.01.017","article-title":"Pregnancy and essential thrombocytemia","volume":"39","author":"Giraudet","year":"2011","journal-title":"Gynecol Obstet Fertil"},{"key":"zoi190487r32","article-title":"Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms [published online June 26, 2018].","author":"Lapoirie","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"6","key":"zoi190487r33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/ejh.2004.73.issue-6","article-title":"Pregnancy in essential thrombocythaemia: experience with 40 pregnancies.","volume":"73","author":"Niittyvuopio","year":"2004","journal-title":"Eur J Haematol"},{"issue":"1","key":"zoi190487r34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/(ISSN)1096-8652","article-title":"Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases.","volume":"53","author":"Pagliaro","year":"1996","journal-title":"Am J Hematol"},{"issue":"2","key":"zoi190487r35","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1182\/blood-2007-01-071068","article-title":"Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation.","volume":"110","author":"Passamonti","year":"2007","journal-title":"Blood"},{"issue":"4","key":"zoi190487r36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/1753495X17708896","article-title":"Pregnancy and myeloproliferative neoplasms: a retrospective monocentric cohort.","volume":"10","author":"Puyade","year":"2017","journal-title":"Obstet Med"},{"issue":"2S","key":"zoi190487r38","doi-asserted-by":"publisher","first-page":"S829","DOI":"10.1016\/j.ajog.2017.11.565","article-title":"The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction.","volume":"218","author":"Groom","year":"2018","journal-title":"Am J Obstet Gynecol"},{"issue":"16","key":"zoi190487r39","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1001\/jama.2017.3439","article-title":"Screening for preeclampsia: US Preventive Services Task Force recommendation statement.","volume":"317","author":"Bibbins-Domingo","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"zoi190487r40","doi-asserted-by":"publisher","first-page":"e000101","DOI":"10.1136\/bmjopen-2011-000101","article-title":"Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study.","volume":"1","author":"Roberts","year":"2011","journal-title":"BMJ Open"},{"issue":"6","key":"zoi190487r41","doi-asserted-by":"publisher","first-page":"476.e1","DOI":"10.1016\/j.ajog.2013.02.042","article-title":"The incidence of preeclampsia and eclampsia and associated maternal mortality in Australia from population-linked datasets: 2000-2008.","volume":"208","author":"Thornton","year":"2013","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"zoi190487r42","doi-asserted-by":"publisher","first-page":"695","DOI":"10.7326\/M13-2844","article-title":"Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the US Preventive Services Task Force.","volume":"160","author":"Henderson","year":"2014","journal-title":"Ann Intern Med"},{"issue":"7","key":"zoi190487r43","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia.","volume":"377","author":"Rolnik","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi190487r44","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1182\/blood-2016-09-728006","article-title":"Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis.","volume":"129","author":"Skeith","year":"2017","journal-title":"Blood"},{"issue":"3","key":"zoi190487r45","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.reprotox.2011.11.003","article-title":"A systematic review of the fetal safety of interferon alpha.","volume":"33","author":"Yazdani Brojeni","year":"2012","journal-title":"Reprod Toxicol"},{"issue":"6","key":"zoi190487r46","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood.V96.6.2093","article-title":"Interferon-a directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1.","volume":"96","author":"Wang","year":"2000","journal-title":"Blood"},{"issue":"3","key":"zoi190487r47","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/bjh.2010.149.issue-3","article-title":"Guideline for investigation and management of adults and children presenting with a thrombocytosis.","volume":"149","author":"Harrison","year":"2010","journal-title":"Br J Haematol"},{"issue":"7","key":"zoi190487r48","first-page":"CD004734","article-title":"Aspirin and\/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia.","author":"de Jong","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"zoi190487r49","first-page":"CD006780","article-title":"Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction.","author":"Dodd","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"zoi190487r50","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/bjh.2015.168.issue-5","article-title":"LMWH to prevent placenta-mediated pregnancy complications: an update.","volume":"168","author":"Duffett","year":"2015","journal-title":"Br J Haematol"},{"issue":"18","key":"zoi190487r51","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1182\/blood-2011-07-319749","article-title":"Is heparin a placental anticoagulant in high-risk pregnancies?","volume":"118","author":"Kingdom","year":"2011","journal-title":"Blood"},{"issue":"10060","key":"zoi190487r52","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1016\/S0140-6736(16)31139-4","article-title":"Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials.","volume":"388","author":"Rodger","year":"2016","journal-title":"Lancet"},{"issue":"25","key":"zoi190487r53","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms.","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"zoi190487r54","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi190487r55","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7326\/M17-0284","article-title":"Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review.","volume":"167","author":"Chu","year":"2017","journal-title":"Ann Intern Med"},{"key":"zoi190487r37","volume-title":"Estimated Pregnancy Rates and Rates of Pregnancy Outcomes for the United States, 1990\u20132008","author":"Ventura","year":"2012"},{"key":"zoi190487r14","unstructured":"Wells GA, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed July 19, 2018."},{"key":"zoi190487r16","unstructured":"GRADEpro GDT. GRADEpro Guideline Development Tool. https:\/\/gradepro.org. Accessed September 3, 2019."},{"key":"zoi190487r20","unstructured":"OpenMeta[Analyst]. http:\/\/www.cebm.brown.edu\/openmeta\/. Accessed July 23, 2018."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2752355\/maze_2019_oi_190487.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,8]],"date-time":"2019-12-08T14:56:42Z","timestamp":1575817002000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2752355"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,10,4]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.12666","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,4]]}}}